Chlorpromazine

Summary

Chlorpromazine (CHEMBL71) is an approved small-molecule phenothiazine antipsychotic drug (ATC N05AA01) targeting HTR6, HTR7, and HTR1A; indicated across 11 conditions including psychotic disorder and mental disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05AA01
• Targets: 15 (HTR6, HTR7, HTR1A…)
• Indications: 11 conditions
• Clinical trials: 17
• Chemistry: 318.9 Da · C17H19ClN2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL71
Name	Chlorpromazine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	2726
ChEBI	CHEBI:3647
ATC	N05AA01
Molecular formula	C17H19ClN2S
Molecular weight	318.9
InChIKey	ZPEIMTDSQAKGNT-UHFFFAOYSA-N

SMILES: CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl

IUPAC name: 3-(2-chlorophenothiazin-10-yl)-N,N-dimethylpropan-1-amine

ChEBI definition: A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.

Pharmacological roles (ChEBI): phenothiazine antipsychotic drug, antiemetic, dopaminergic antagonist, EC 3.4.21.26 (prolyl oligopeptidase) inhibitor, anticoronaviral agent.

Also known as: Aminazine, Chlorpromazine, Chlorpromazinum, Clorpromazina, Esmind, Elmarin, Fenactil, J2.794D, Largactilothiazine, Megaphen, Novomazina, NSC-167745

Parent form; salt/anhydrous children: CHEMBL1713

Patent coverage: 13,992 distinct patent families (45,827 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 45,540 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
HTR6	5-HT6 receptor	Inverse agonist	7.8	0.2%	P50406
HTR7	5-HT7 receptor	Inverse agonist	7.6	0.8%	P34969
HTR1A	5-HT1A receptor	Antagonist	6.2	0%	P08908
DRD1	D1 receptor	Antagonist	7.1	0%	P21728
DRD2	D2 receptor	Antagonist	7.6	0%	P14416
DRD3	D3 receptor	Antagonist	7.5	0%	P35462
DRD4	D4 receptor	Antagonist	7.8	0%	P21917
DRD5	D5 receptor	Antagonist	6.9	0%	P21918
ADRA2A	α2A-adrenoceptor	Antagonist	6.6	0.1%	P08913
HRH1	H1 receptor	Antagonist	8.2	0%	P35367
ADRA2B	α2B-adrenoceptor	Antagonist	8.3	0.2%	P18089
ADRA2C	α2C-adrenoceptor	Antagonist	7.4	0%	P18825
TRPC5	TRPC5			0%	Q9UL62
HTR2A	5-HT2A receptor	Inverse agonist	8.1	0%	P28223
	Maxi Cl-
HTR2C	5-HT2C receptor	Antagonist	8.2	0%	P28335

Broader ChEMBL bioactivity targets: 105 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Microtubule-associated protein tau, Survival motor neuron protein, Prelamin-A/C, 4’-phosphopantetheinyl transferase ffp, Thrombopoietin, Ras-related protein Rab-9A, Aldehyde oxidase 1, Pleiotropic ABC efflux transporter of multiple drugs, Muscarinic acetylcholine receptor M4.

Bioactivity

ChEMBL activities: 253 potent at pChembl ≥ 5 of 307 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P08909	9.15	Ki	0.7	nM	CHEMBL_ACT_315933
DRD2	9	IC50	1	nM	CHEMBL_ACT_15186915
DRD2	9	IC50	1	nM	CHEMBL_ACT_15187892
HTR2A	8.96	Ki	1.1	nM	CHEMBL_ACT_7709903
DRD2	8.92	Ki	1.2	nM	CHEMBL_ACT_12074128
P61169	8.92	Ki	1.2	nM	CHEMBL_ACT_461839
DRD3	8.8	Ki	1.58	nM	CHEMBL_ACT_1925176
P15823	8.8	Ki	1.58	nM	CHEMBL_ACT_1925454
P61169	8.75	Ki	1.77	nM	CHEMBL_ACT_378876
DRD2	8.74	Ki	1.8	nM	CHEMBL_ACT_19098532
DRD2	8.74	Ki	1.8	nM	CHEMBL_ACT_19248922
ADRA1D	8.71	Ki	1.96	nM	CHEMBL_ACT_7705579
HRH1	8.71	Ki	1.96	nM	CHEMBL_ACT_7707720
P61169	8.7	Ki	2.01	nM	CHEMBL_ACT_611404
P61169	8.7	Ki	2	nM	CHEMBL_ACT_935196
P18901	8.67	IC50	2.15	nM	CHEMBL_ACT_704339
P61169	8.66	Ki	2.19	nM	CHEMBL_ACT_378877
DRD2	8.63	Ki	2.34	nM	CHEMBL_ACT_24412797
HTR2C	8.56	Ki	2.74	nM	CHEMBL_ACT_7709907
DRD2	8.52	IC50	3	nM	CHEMBL_ACT_18530272
P61169	8.52	Ki	3	nM	CHEMBL_ACT_209816
DRD3	8.52	Ki	3	nM	CHEMBL_ACT_708505
DRD3	8.48	Ki	3.31	nM	CHEMBL_ACT_13876489
DRD3	8.48	Ki	3.3	nM	CHEMBL_ACT_13876524
P08909	8.48	Ki	3.3	nM	CHEMBL_ACT_611406
P08909	8.48	Ki	3.31	nM	CHEMBL_ACT_935198
HTR2A	8.47	IC50	3.4	nM	CHEMBL_ACT_13828626
P43140	8.46	Ki	3.46	nM	CHEMBL_ACT_7705575
DRD3	8.42	Ki	3.8	nM	CHEMBL_ACT_12074122
HTR2A	8.41	IC50	3.85	nM	CHEMBL_ACT_7709902

Target pathways

Aggregated over 15 target gene(s): HTR6, HTR7, HTR1A, DRD1, DRD2, DRD3, DRD4, DRD5, ADRA2A, HRH1, ADRA2B, ADRA2C, TRPC5, HTR2A, HTR2C.

Top Reactome pathways

27 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	8	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR2A, HTR2C, HTR6, HTR7
Signaling by GPCR	8	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR2A, HTR2C, HTR6, HTR7
Class A/1 (Rhodopsin-like receptors)	8	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR2A, HTR2C, HTR6, HTR7
Amine ligand-binding receptors	8	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR2A, HTR2C, HTR6, HTR7
GPCR ligand binding	8	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR2A, HTR2C, HTR6, HTR7
GPCR downstream signalling	7	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C, HTR6, HTR7
Dopamine receptors	5	DRD1, DRD2, DRD3, DRD4, DRD5
Serotonin receptors	5	HTR1A, HTR2A, HTR2C, HTR6, HTR7
G alpha (i) signalling events	5	ADRA2A, ADRA2B, ADRA2C, DRD3, DRD4
G alpha (s) signalling events	4	DRD1, DRD5, HTR6, HTR7
Hemostasis	3	ADRA2A, ADRA2B, ADRA2C
Adrenoceptors	3	ADRA2A, ADRA2B, ADRA2C
Adrenaline signalling through Alpha-2 adrenergic receptor	3	ADRA2A, ADRA2B, ADRA2C
G alpha (q) signalling events	3	HRH1, HTR2A, HTR2C
G alpha (z) signalling events	3	ADRA2A, ADRA2B, ADRA2C
Platelet activation, signaling and aggregation	3	ADRA2A, ADRA2B, ADRA2C
Platelet Aggregation (Plug Formation)	3	ADRA2A, ADRA2B, ADRA2C
Metabolism	2	ADRA2A, ADRA2C
Integration of energy metabolism	2	ADRA2A, ADRA2C
Metabolism of proteins	2	ADRA2A, ADRA2C
Adrenaline,noradrenaline inhibits insulin secretion	2	ADRA2A, ADRA2C
Regulation of insulin secretion	2	ADRA2A, ADRA2C
Surfactant metabolism	2	ADRA2A, ADRA2C
TRP channels	1	TRPC5
Histamine receptors	1	HRH1
Role of second messengers in netrin-1 signaling	1	TRPC5
RHOBTB3 ATPase cycle	1	HTR7

Dominant GO biological processes

GO term	Targets
signal transduction	14
G protein-coupled receptor signaling pathway	14
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	8
chemical synaptic transmission	8
G protein-coupled serotonin receptor signaling pathway	6
positive regulation of MAPK cascade	6
intracellular calcium ion homeostasis	6
behavioral response to cocaine	5
phospholipase C-activating dopamine receptor signaling pathway	5
synaptic transmission, dopaminergic	5
response to cocaine	5
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	4
behavioral fear response	4
positive regulation of cell population proliferation	4
regulation of vasoconstriction	4

Indications & clinical

Indications

11 indications (6 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
psychotic disorder	4	MONDO:0005485	EFO:0005407
mental disorder	4	MONDO:0005084	EFO:0000677
conduct disorder	4	MONDO:0005352	EFO:0004216
porphyria	4	MONDO:0037939	MONDO:0037939
neonatal abstinence syndrome	3	MONDO:0005566	EFO:0005799
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096
delirium	2	MONDO:0045057	EFO:0009267
glioblastoma	2	MONDO:0018177	EFO:0000519
colonic neoplasm	1	MONDO:0005401	MONDO:0021063

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 17.

Phase distribution

Phase	Trials
PHASE4	4
PHASE3	3
PHASE2/PHASE3	3
Not specified	3
PHASE1	2
PHASE2	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00169039	PHASE4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00202293	PHASE4	COMPLETED	Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features
NCT00654576	PHASE4	COMPLETED	Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With Schizophrenia
NCT03639558	PHASE4	COMPLETED	TREC-Lebanon: A Trial for Rapid Tranquilisation for Agitated Patients in the Emergency Setting
NCT03021486	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer
NCT05431595	PHASE2/PHASE3	RECRUITING	Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy
NCT00882518	PHASE3	COMPLETED	Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients
NCT02810782	PHASE3	COMPLETED	How to Treat Opiate Withdrawal in Neonates
NCT04354805	PHASE2/PHASE3	UNKNOWN	Administration of Chlorpromazine as a Treatment for COVID-19
NCT04366739	PHASE3	WITHDRAWN	Repurposing of Chlorpromazine in Covid-19 Treatment
NCT04224441	PHASE2	UNKNOWN	Repurposing Chlorpromazine in the Treatment of Glioblastoma
NCT05433402	PHASE1/PHASE2	WITHDRAWN	Repurposing the Antipsychotic Drug Chlorpromazine as Adjuvant Therapeutic Agent for Resected Stage III Colon Cancer
NCT06663631	PHASE1	RECRUITING	Study on Hibernation-like Therapy Based on Mechanical Thrombectomy
NCT05190315	PHASE1	COMPLETED	Chlorpromazine and Standard of Care in Glioblastoma
NCT01404364	Not specified	COMPLETED	Use of Intravitreal Triamcinolone and Retrobulbar Chlorpromazine as Alternatives to the Management of Painful Blind Eye
NCT02600741	Not specified	COMPLETED	Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)
NCT03183310	Not specified	UNKNOWN	The Effect of Chlorpromazine on Esophageal Sensitivity in Healthy Volunteers.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 1 clinical and 5 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

986 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
BREXPIPRAZOLE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
CLOZAPINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
DIHYDROERGOTAMINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
OLANZAPINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
AMOXAPINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
CARIPRAZINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
DOXEPIN	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
FLUPHENAZINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
HALOPERIDOL	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
LOXAPINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
PROMAZINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
RISPERIDONE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
RITANSERIN	ChEMBL	Phase 2	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
TEGASEROD	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR2C, HTR6, HTR7
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
IMIPRAMINE	ChEMBL	Phase 4 (approved)	ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
MIANSERIN	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
NEFAZODONE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
QUETIAPINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
THIORIDAZINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
THIOTHIXENE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
ZIPRASIDONE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
PENFLURIDOL	ChEMBL	Phase 2	ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
SPIPERONE	ChEMBL	Phase 2	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
Pyrazinamide	PubChem	Approved	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
DESLORATADINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6
PALIPERIDONE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR2A, HTR2C, HTR7
PRAMIPEXOLE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR7
APOMORPHINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2C
ASENAPINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6
CARVEDILOL	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2C, HTR6, HTR7
CYPROHEPTADINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
EBASTINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6
ILOPERIDONE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6
KETANSERIN	ChEMBL	Phase 4 (approved)	ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
KETOTIFEN	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD5, HRH1, HTR2A, HTR2C, HTR6, HTR7
MAPROTILINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6
METHYSERGIDE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
PERGOLIDE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6
PIMOZIDE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6
PROCHLORPERAZINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6
PROMETHAZINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6
SERTINDOLE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6
SUNITINIB	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6
LISURIDE	ChEMBL	Phase 3	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6
FANANSERIN	ChEMBL	Phase 2	ADRA2A, ADRA2B, ADRA2C, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
METERGOLINE	ChEMBL	Phase 2	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7
NIGULDIPINE	ChEMBL	Phase 2	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD5, HRH1, HTR1A, HTR2C, HTR6, HTR7
Fidaxomicin	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2C
Propoxyphene	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2C
AZELASTINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, HRH1, HTR2A, HTR2C, HTR6, HTR7
BENPERIDOL	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2C
BROMOCRIPTINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2C, HTR6
CABERGOLINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A
CISAPRIDE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, HRH1, HTR1A, HTR2A, HTR2C, HTR7
CLEMASTINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, HRH1, HTR1A, HTR2A, HTR2C, HTR6
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, HRH1, HTR1A, HTR2A, HTR2C, HTR6
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR2A, HTR2C, HTR6